Received by email:

File: 08 20 2015 PrivatePlacement_Close_FINAL.docx

ABATTIS ANNOUNCES PRIVATE PLACEMENT

Vancouver, BC - August 20, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX: ATTBF) (CSE: ATT), a
---> Company that develops and commercializes natural health (nutraceutical) products and conducts research and developmen
--->t to creatge plant-based (botanical) intellectual property and ingredients for the pharmaceutical, nutraceutical, bioc
--->eutical and cosmetic markets - some of which will contain cannabinoid compounds, would like to announce the close of t
--->hee private placement announced  private placement of up to $297,454.  
Under the terms of the Private Placement, Abattis will issue up to 5,949,080 Units. Each Unit will consist of one Comm
--->on Share at $0.05 per share, and one full Share Purchase Warrant.  One Warrant will be exercisable into one Common Sha
--->re at a price of $0.09 per Common Share.  The expiry date for the exercise of the Warrants will be 24 months after the
---> closing of this Unit Offering. 
Proceeds of this offering will be used for the production and sale of hemp water, research and development, marketing,
---> working capital, general corporate purposes. The Shares will be subject to a Canadian resale hold period expiring fou
--->r months and one day from the closing.
Further, the Company is pleased to announce that, in compliance with the Company's option plan, the Company has grante
--->d 3,900,000 incentive stock options to certain of its directors, officers and consultants, with each option being exer
--->cisable into a common share of Abattis at $0.06 per share for a period of five years.
About Abattis Bioceuticals Corp. 
Abattis is a specialty biotechnology company that aggregates, incubates, integrates and invests in the botanical drug 
--->development industry.  The Company develops and licenses natural health products, medicines, extractions and ingredien
--->ts for the biologics, nutraceutical, bioceutical and cosmetic markets - some of which will contain cannabinoid compoun
--->ds. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expa
--->nding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canad
--->a and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.
ON BEHALF OF THE BOARD
"Bill Fleming" Bill Fleming, CEO
For further information, contact the Company at (604) 336-0881 or at news@abattis.com.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY 
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words "antic
--->ipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are in
--->tended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on 
--->which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-look
--->ing statements because the Company can give no assurance that they will prove to be correct. Since forward-looking sta
--->tements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Thes
--->e statements speak only as of the date of this press release. Actual results could differ materially from those curren
--->tly anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Disc
--->ussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertak
--->e to update this information at any particular time.


File: 08 20 2015 PrivatePlacement_Close_FINAL.pdf


  
Suite
  1040
   
  885
  West
  Georgia
  Street,
  
  
Vancouver,
  BC
  
  
  V6C
  3H1
  
Tel:
  604.336.0881
  
Email:
  news@abattis.com
  

  

  



                                                  ABATTIS
  ANNOUNCES
  PRIVATE
  PLACEMENT
  

  
Vancouver,
  BC
   
  August
  20,
  2015
  -
  Abattis
  Bioceuticals
  Corp.
  (the
  "Company"
  or
  "Abattis")
  (OTCQX:
  ATTBF)
  (CSE:
  ATT),
  a
  
Company
  that
  develops
  and
  commercializes
  natural
  health
  (nutraceutical)
  products
  and
  conducts
  research
  and
  
development
  to
  creatge
  plant-based
  (botanical)
  intellectual
  property
  and
  ingredients
  for
  the
  pharmaceutical,
  nutraceutical,
  
bioceutical
  and
  cosmetic
  markets
  -
  some
  of
  which
  will
  contain
  cannabinoid
  compounds,
  would
  like
  to
  announce
  the
  close
  of
  
thee
  private
  placement
  announced
  
  private
  placement
  of
  up
  to
  $297,454.
  
  
  

Under
  the
  terms
  of
  the
  Private
  Placement,
  Abattis
  will
  issue
  up
  to
  5,949,080
  Units.
  Each
  Unit
  will
  consist
  of
  one
  Common
  
Share
  at
  $0.05
  per
  share,
  and
  one
  full
  Share
  Purchase
  Warrant.
  
  One
  Warrant
  will
  be
  exercisable
  into
  one
  Common
  Share
  at
  
a
  price
  of
  $0.09
  per
  Common
  Share.
  
  The
  expiry
  date
  for
  the
  exercise
  of
  the
  Warrants
  will
  be
  24
  months
  after
  the
  closing
  of
  
this
  Unit
  Offering.
  
  

Proceeds
  of
  this
  offering
  will
  be
  used
  for
  the
  production
  and
  sale
  of
  hemp
  water,
  research
  and
  development,
  marketing,
  
working
  capital,
  general
  corporate
  purposes.
  The
  Shares
  will
  be
  subject
  to
  a
  Canadian
  resale
  hold
  period
  expiring
  four
  
months
  and
  one
  day
  from
  the
  closing.
  

Further,
  the
  Company
  is
  pleased
  to
  announce
  that,
  in
  compliance
  with
  the
  Company's
  option
  plan,
  the
  Company
  has
  
granted
  3,900,000
  incentive
  stock
  options
  to
  certain
  of
  its
  directors,
  officers
  and
  consultants,
  with
  each
  option
  being
  
exercisable
  into
  a
  common
  share
  of
  Abattis
  at
  $0.06
  per
  share
  for
  a
  period
  of
  five
  years.
  

About
  Abattis
  Bioceuticals
  Corp.
  
  

Abattis
  is
  a
  specialty
  biotechnology
  company
  that
  aggregates,
  incubates,
  integrates
  and
  invests
  in
  the
  botanical
  drug
  
development
  industry.
  
  The
  Company
  develops
  and
  licenses
  natural
  health
  products,
  medicines,
  extractions
  and
  ingredients
  
for
  the
  biologics,
  nutraceutical,
  bioceutical
  and
  cosmetic
  markets
   
  some
  of
  which
  will
  contain
  cannabinoid
  compounds.
  The
  
Company
  also
  has
  an
  extensive
  pipeline
  of
  high-quality
  products
  and
  intellectual
  property
  for
  the
  rapidly
  expanding
  
botanical
  drug
  market.
  We
  follow
  strict
  standard
  operating
  protocols,
  and
  adhere
  to
  the
  applicable
  laws
  of
  Canada
  and
  
foreign
  jurisdictions.
  For
  more
  information,
  visit
  the
  Company's
  website
  at:
  www.abattis.com.
  

ON
  BEHALF
  OF
  THE
  BOARD
  

"Bill
  Fleming"
  
Bill
  Fleming,
  CEO
  

For
  further
  information,
  contact
  the
  Company
  at
  (604)
  336-0881
  or
  at
  news@abattis.com.
  

NEITHER
  THE
  CANADIAN
  SECURITIES
  EXCHANGE
  NOR
  ITS
  REGULATIONS
  SERVICES
  PROVIDER
  HAVE
  REVIEWED
  OR
  ACCEPT
  
RESPONSIBILITY
  FOR
  THE
  ADEQUACY
  OR
  ACCURACY
  OF
  THIS
  RELEASE.
  

FORWARD
  LOOKING
  INFORMATION
  
This
  press
  release
  contains
  forward-looking
  statements.
  The
  use
  of
  any
  of
  the
  words
  "anticipate",
  "continue",
  "estimate",
  "expect",
  "may",
  "will",
  
"project",
  "should",
  "believe"
  and
  similar
  expressions
  are
  intended
  to
  identify
  forward-looking
  statements.
  Although
  the
  Company
  believes
  that
  the
  
expectations
  and
  assumptions
  on
  which
  the
  forward-looking
  statements
  are
  based
  are
  reasonable,
  undue
  reliance
  should
  not
  be
  placed
  on
  the
  forward-
looking
  statements
  because
  the
  Company
  can
  give
  no
  assurance
  that
  they
  will
  prove
  to
  be
  correct.
  Since
  forward-looking
  statements
  address
  future
  events
  
and
  conditions,
  by
  their
  very
  nature
  they
  involve
  inherent
  risks
  and
  uncertainties.
  These
  statements
  speak
  only
  as
  of
  the
  date
  of
  this
  press
  release.
  Actual
  
 
  
Suite
  1040
   
  885
  West
  Georgia
  Street,
  
  
Vancouver,
  BC
  
  
  V6C
  3H1
  
Tel:
  604.336.0881
  
Email:
  news@abattis.com
  

  

  


results
  could
  differ
  materially
  from
  those
  currently
  anticipated
  due
  to
  a
  number
  of
  factors
  and
  risks
  various
  risk
  factors
  discussed
  in
  the
  Company's
  
Management's
  Discussion
  and
  Analysis
  under
  the
  Company's
  profile
  on
  www.sedar.com.
  While
  the
  Company
  may
  elect
  to,
  it
  does
  not
  undertake
  to
  update
  
this
  information
  at
  any
  particular
  time.